The COPD Assessment Test (CAT) questionnaire is a valid method to measure health-related quality of life (QoL) in bronchiectasis, according to the results of a study published in the journal CHEST.
Researchers from multiple institutions in Spain conducted this observational, multicenter, prospective study. Patients with bronchiectasis were given the CAT questionnaire and psychometric properties of the questionnaire were measured. Outcomes of interest were internal consistency, repeatability, discriminant validity, convergent validity, longitudinal validity, predictive validity to future exacerbations, and minimum clinically important difference.
Among the 96 patients who were administered the test, the mean age was 62.2 years and the average follow-up was 1 year. The CAT showed excellent consistency and repeatability. However, the correlations with severity scores had a Pearson coefficient between 0.22 and 0.26. CAT values ≥10 points had a prognostic value for patients with >1 exacerbation. Finally, the minimum clinically important difference was determined to be 3 points.
The study did have several limitations, including a lack of external validation in patient populations with different characteristics from those in the Spanish population and a lack of assessment of CAT score changes in response to certain treatments (eg, inhaled antibiotics or macrolides).
“These findings, combined with the fact that the CAT is easy to use and to interpret, make it ideally suited to use in everyday clinical practice,” the authors concluded.
Disclosure: This study was supported by Grupo Praxis Pharmaceutical SL. Please see the original reference for a full list of authors’ disclosures.
De la Rosa Carrillo D, Olveira-Fuster C, García-Clemente M, et al. CAT (COPD Assessment Test) in bronchiectasis: minimum clinically important difference and psychometric validation. A prospective study [published August 22, 2019]. CHEST. doi:10.1016/j.chest.2019.08.1916